2016
Well-Differentiated Syringofibrocarcinoma in a Patient With Clouston Syndrome
Odell ID, Lilly E, Reeve K, Bosenberg MW, Milstone LM. Well-Differentiated Syringofibrocarcinoma in a Patient With Clouston Syndrome. JAMA Dermatology 2016, 152: 484. PMID: 26792110, DOI: 10.1001/jamadermatol.2015.4496.Peer-Reviewed Case Reports and Technical NotesCutaneous Vasculopathy as an Adverse Effect of the Anti–Vascular Endothelial Growth Factor Agent Axitinib
Shi VJ, Galan A, Odell ID, Choi JN. Cutaneous Vasculopathy as an Adverse Effect of the Anti–Vascular Endothelial Growth Factor Agent Axitinib. JAMA Dermatology 2016, 152: 222. PMID: 26509864, DOI: 10.1001/jamadermatol.2015.3209.Peer-Reviewed Original Research
2015
Somatic p.T771R KDR (VEGFR2) Mutation Arising in a Sporadic Angioma During Ramucirumab Therapy
Lim YH, Odell ID, Ko CJ, Choate KA. Somatic p.T771R KDR (VEGFR2) Mutation Arising in a Sporadic Angioma During Ramucirumab Therapy. JAMA Dermatology 2015, 151: 1240-1243. PMID: 26422291, DOI: 10.1001/jamadermatol.2015.1925.Peer-Reviewed Original ResearchConceptsVascular endothelial growth factor 2Vascular lesionsRamucirumab therapyNon-small cell lung carcinomaExome sequencingNew vascular lesionsMetastatic rectal cancerCell lung carcinomaRich blood supplySomatic mutationsInhibition of angiogenesisVia exome sequencingPotential adverse effectsRight shinAntiangiogenic therapeuticsGrowth factor 2Rectal cancerCombination therapyVascular tumorsGastric adenocarcinomaHistological featuresLung carcinomaBlood supplyRight legIrinotecan hydrochloride